Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

Sponsor
University of Zurich
Study ID
NCT03553433
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast 30mg — DRUG
    Anti-psoriatic drug
  • Placebo Oral Tablet — DRUG
    Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Study Details

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Key Dates

First listed
Jun 12, 2018
Start date
Jun 30, 2018
Status verified
Jun 2018
Primary completion
Dec 31, 2019
Completion
Jun 30, 2020

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Verum
    Apremilast 30mg bd
  • Placebo Comparator: Placebo Oral Tablet
    Excipiens

Primary Outcome Measure

Scalp VAS Pruritus assessment [ Time Frame: Weeks 16 ]

Central Contacts

Related Studies